Home » Stocks » Royalty Pharma

Royalty Pharma PLC (RPRX)

Stock Price: $43.41 USD -0.66 (-1.49%)
Updated Jul 14, 2020 1:21 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 26.35B
Revenue (ttm) 1.88B
Net Income (ttm) n/a
Shares Out 365.83M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $43.41
Previous Close $44.06
Change ($) -0.66
Change (%) -1.49%
Day's Open 44.00
Day's Range 41.53 - 44.99
Day's Volume 1,983,624
52-Week Range 41.53 - 56.50

More Stats

Market Cap 26.35B
Enterprise Value 30.61B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 365.83M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.01M
Short Ratio 0.32
Short % of Float 0.76%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.01
PB Ratio 5.69
Revenue 1.88B
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash -4.26B
Net Cash / Share -7.02
Gross Margin 150.70%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 3
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(19.80% upside)
Current: 43.41
Target: 52.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth1.08%12.33%-
Gross Profit1,8141,7951,598
Operating Income2,6231,364940
Net Income2,3491,3781,210
Operating Cash Flow1,6671,6181,418
Capital Expenditures-250--
Free Cash Flow1,4171,6181,418
Cash & Equivalents7932,3860.00
Total Debt6,2386,519-
Net Cash / Debt-5,445-4,1330.00
Book Value6,1064,488-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Royalty Pharma PLC
Country United States
CEO Pablo Gerardo Legorreta

Stock Information

Ticker Symbol RPRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RPRX
IPO Date June 16, 2020


Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. It has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. The company was founded in 1996 and is based in New York, New York.